EIGR - Eiger BioPharmaceuticals

-

$undefined

N/A

(N/A)

Eiger BioPharmaceuticals NasdaqGM:EIGR Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Location: 2155 Park Boulevard, Palo Alto, CA, 94306, United States | Website: https://www.eigerbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.88M

Cash

44.43M

Avg Qtr Burn

-20.71M

Short % of Float

2.64%

Insider Ownership

11.80%

Institutional Own.

43.86%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zokinvy™ (lonafarnib) Details
Progeroid laminopathies, Progeria, Hutchinson-Gilford progeria syndrome

Approved

Quarterly sales

Lonafarnib Details
Liver disease, Infectious disease, Hepatitis D

Phase 3

Update

Avexitide (GLP-1 Antagonist) Details
Metabolic disorder, Congenital Hyperinsulinism

Phase 3

Update

Avexitide (GLP-1 Antagonist) Details
Post-Bariatric Hypoglycemia, Metabolic disorder, Rare diseases

Phase 3

Update

Peginterferon Lambda + Lonafarnib Details
Infectious disease, Hepatitis D

Phase 2

Update

Peginterferon Lambda (Lambda) Details
Infectious disease, Hepatitis D

Failed

Discontinued

Failed

Discontinued